Gerald L. Andriole, Jr., MD
Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 25 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 300 peer-reviewed publications and abstracts and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and is on the Steering Committee of the REDUCE Prostate Cancer Prevention Trial. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association and the American Association of Genitourinary Surgeons among other societies.
Christopher J. Kane, MD
Christopher J. Kane, MD, Dean of Clinical Affairs and CEO of UC San Diego Health Physicians, is a board-certified urologist who specializes in treating patients with prostate cancer. He has extensive expertise in robotic prostatectomy, open and laparoscopic kidney cancer surgery, and bladder and testes cancer surgery.
Dr. Kane performs over 200 robotic cancer surgeries per year and is highly experienced in nerve sparing robotic prostatectomies, robotic radical cystectomy for bladder cancer, and robotic partial nephrectomy for kidney cancer. He is internationally recognized for patient care and research in prostate cancer, renal cell carcinoma, robotic and minimally invasive surgical treatment of urologic diseases and disorders, and risk stratification and outcomes after treatment.
Dr. Kane has authored more than 240 peer-reviewed research articles with a focus on prostate cancer risk factors and outcomes, prostate cancer surgery and minimally invasive surgery for prostate and kidney cancer. He serves on the editorial boards of several major urology journals as well as the National Comprehensive Cancer Network (NCCN) Prostate Cancer Management Guidelines Committee. He also co-chairs the National Cancer Institute’s Renal Cell Carcinoma Advisory Task Force.
Dr. Kane completed his residency at the Naval Medical Center in Oakland, California. He received his medical degree from Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Kane is board certified in urology.
A. Karim Kader, MD, PhD
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in detecting, treating and preventing prostate cancer.
As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include genetic markers of risk and outcome in urologic cancer. In addition he is examining the impact of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center in Houston and a residency in urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is board certified in urology.
Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
Dr. Franklin Gaylis
Dr. Franklin Gaylis graduated in the top 5% of his medical school class at the University of Witwatersrand in Johannesburg, South Africa, with a MBBCh degree (Cum Laude) in 1980. After a year of basic science research, Dr. Gaylis completed his General Surgical training requirements at the University of Minnesota before moving to Chicago where he completed his specialty training in Urology at Northwestern University Medical School. During his basic science research year at Northwestern University, Dr. Gaylis studied prostate cancer and has published extensively. He was nominated to the distinguished Alpha Omega Alpha Medical Honor Society by the students of Northwestern Medical School.
Dr. Gaylis is Board Certified and his practice included all aspects of urology with a focus in prostate cancer. He has an academic appointment at the University of California, San Diego, as voluntary Clinical Professor of Urology and serves as Chief Scientific Officer at Genesis Healthcare Partners an integrated Community Urology Group. Dr. Gaylis has been principal investigator in several clinical research studies in collaboration with UCSD.
Dr. Gaylis is a fellow on the American College of Surgeons, received the Sharp Grossmont Hospital Physician Philanthropy award for 2009 and has been recognized as one of San Diego’s Top Doctors.